- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Jindalee Lithium
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative
Advanced Proteome Therapeutics (TSXV:APC) (FSE:0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates. As quoted in the press release: APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has …
Advanced Proteome Therapeutics (TSXV:APC) (FSE:0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates.
As quoted in the press release:
APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has previously been available in the field of radiopharmaceuticals.
The Company is now pleased to disclose that it has successfully created antibody-chelator conjugates site-selectively. This has been accomplished by combining the blockbuster antibody Trastuzumab, used primarily in the treatment of breast cancer, with industry standard DOTA chelators used in targeted Beta particle therapy employing Lutetium-177, as well as other radionuclides.
To the Company’s knowledge, this work provides the first examples of antibody-chelator conjugates that have been produced site-selectively by chemical modification at preferred lysine residues of the native antibody. APC’s approach has the further advantage that the chemical composition of the antibody framework itself does not require labor intensive modification prior to attachment of the chelator payload. Thus antibody-chelator conjugates can be rapidly and economically assembled. APC has filed new patents to protect this work and has begun discussions with potential partners to move development forward.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.